Hansen Medical Announces the Filing of 30 New U.S. Patent Applications Related to Flexible Medical Robotics

Hansen Medical Announces the Filing of 30 New U.S. Patent Applications Related 
to Flexible Medical Robotics 
MOUNTAIN VIEW, CA -- (Marketwire) -- 04/01/13 --  Hansen Medical,
Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today
announced that it has recently filed 30 new patent applications with
the U.S. Patent and Trademark Office relating to flexible medical
robotics, based on research and development activities conducted by
the Company. With these new filings, Hansen Medical now owns or has
exclusive rights to approximately 250 issued and pending patent
applications relating to medical robotics, in addition to hundreds of
other related patents and patent applications which the Company has
the right to use under various third party license agreements.  
"Thanks to our talented, innovative and dedicated engineers and
scientists, the level of invention has never been higher at Hansen
Medical than it is today," said Bruce Barclay, president and CEO of
Hansen Medical. "These new patent applications relate to not only our
core intravascular robotics technology, but also other possible
clinical applications of our technology, and a number of different
technical elements critical to the clinical success of medical
robotics, including robotic systems, software, flexible instruments,
sensing, navigation, and imaging. I am more confident than ever that
our intellectual property portfolio, as supplemented by these new
filings, will provide us an even stronger proprietary position for
our current and future products, and increased potential to grow
shareholder value, for years to come." 
"The creativity consistently demonstrated by our technical teams,
supported by our significant investment in R&D, which resulted in
these new filings, has been exceptional," said Will Sutton, COO of
Hansen Medical. "The Company has never filed this many new U.S.
patent applications in a single year in its history, let alone this
early in the year, making this accomplishment all the more
impressive."  
About Hansen Medical, Inc. 
 Hansen Medical, Inc., based in Mountain
View, California, is the global leader in intravascular robotics,
developing products and technology designed to enable the accurate
positioning, manipulation and control of catheters and catheter-ba
sed
technologies. The Company's Magellan(TM) Robotic System, Magellan
Robotic Catheter and related accessories, which are intended to
facilitate navigation to anatomical targets in the peripheral
vasculature and subsequently provide a conduit for manual placement
of therapeutic devices, have undergone both CE marking and 510(k)
clearance and are commercially available in the European Union, and
the U.S. In the European Union, the Company's Sensei(R) X Robotic
Catheter System and Artisan Control Catheter are cleared for use
during electrophysiology (EP) procedures, such as guiding catheters
in the treatment of atrial fibrillation (AF), and the Lynx(R) Robotic
Ablation Catheter is cleared for the treatment of AF. This robotic
catheter system is compatible with fluoroscopy, ultrasound, 3D
surface map and patient electrocardiogram data. In the U.S. the
Company's Sensei X Robotic Catheter System and Artisan Control
Catheter were cleared by the U.S. Food and Drug Administration for
manipulation and control of certain mapping catheters in EP
procedures. In the United States, the Sensei System is not approved
for use in guiding ablation procedures; this use remains
experimental. The U.S. product labeling therefore provides that the
safety and effectiveness of the Sensei X System and Artisan Control
Catheter for use with cardiac ablation catheters in the treatment of
cardiac arrhythmias, including AF, have not been established.
Additional information can be found at www.hansenmedical.com. 
Forward-Looking Statements
 This press release contains
forward-looking statements regarding, among other things, statements
relating to goals, plans, objectives, milestones and future events.
All statements, other than statements of historical fact, are
statements that could be deemed forward-looking statements, including
statements containing the words "plan," "expects," "potential,"
"believes," "goal," "estimate," "anticipates," and similar words.
These statements are based on the current estimates and assumptions
of our management as of the date of this press release and are
subject to risks, uncertainties, changes in circumstances and other
factors that may cause actual results to differ materially from the
information expressed or implied by forward-looking statements made
in this press release. Examples of such statements include statements
about the potential benefits of our technology and the value of our
intellectual property portfolio. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, among others: engineering,
regulatory, manufacturing, sales and customer service challenges in
developing new products and entering new markets; potential safety
and regulatory issues that could slow or suspend our sales; the
effect of credit, financial and economic conditions on capital
spending by our potential customers; the uncertain timelines for the
sales cycle for newly introduced products; the rate of adoption of
our systems and the rate of use of our catheters; the scope and
validity of intellectual property rights applicable to our products;
competition from other companies; our ability to recruit and retain
key personnel; our ability to maintain our remedial actions over
previously reported material weaknesses in internal controls over
financial reporting; our ability to manage expenses and cash flow,
and obtain additional financing; and other risks more fully described
in the "Risk Factors" section of our Annual Report on Form 10-K for
the year ended December 31, 2012 filed with the SEC on March 18, 2013
and the risks discussed in our other reports filed with the SEC.
Given these uncertainties, you should not place undue reliance on the
forward-looking statements in this press release. We undertake no
obligation to revise or update information herein to reflect events
or circumstances in the future, even if new information becomes
available. 
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan and
NorthStar are trademarks of Hansen Medical, Inc. in the United States
and other countries. 
Investor Contacts:
Peter J. Mariani
Chief Financial Officer
Hansen Medical, Inc.
650.404.5800 
FTI Consulting, Inc.
Brian Ritchie
212.850.5683
brian.ritchie@fticonsulting.com 
John Capodanno
212.850.5705
john.capodanno@fticonsulting.com 
 
 
Press spacebar to pause and continue. Press esc to stop.